Experimental obesity drug outperforms traditional weight-loss treatments in early research

A new weight-loss drug variation is showing promise in early trials.

Research from the Institute for Diabetes and Obesity at Helmholtz Munich in Germany, published in the journal Nature, tested an experimental obesity and diabetes drug called GLP-1-GIP-Lani.

The drug combines GLP-1 and GIP — two natural hormones that help regulate appetite and blood sugar, similar to popular weight-loss drugs like Ozempic — with PPAR activity, which may improve insulin sensitivity, inflammation, fat metabolism and liver health.